Find clinical trials | Bayside Health (Alfred)

DRI19220

A randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study of brivekimig followed by a maintenance period in participants with moderate to severe hidradenitis suppurativa [BRIGHTEN] (NCT07170917)

The purpose of this study is to assess the efficacy and safety of brivekimig in a dose-ranging study of participants with moderate to severe Hidradenitis Suppurativa (HS). Participants will be in the study for up to 60 weeks and have the option to enter a long-term extension study for an additional 52 weeks. The treatment will be administered via subcutaneous injection (small injection into the abdomen) every two weeks.

Currently recruiting

DROP-FPF

A double blind, randomized, placebo-controlled exploratory trial to investigate the efficacy and safety of nerandomilast over 24 months when administered in individuals with interstitial lung abnormalities and a family history of pulmonary fibrosis to reduce the risk of worsening (NCT07201922)

A double blind, randomized, placebo-controlled exploratory trial to investigate the efficacy and safety of nerandomilast over 24 months when administered in individuals with interstitial lung abnormalities and a family history of pulmonary fibrosis to reduce the risk of worsening.

Currently recruiting

DSP107_003

A Randomized, Open-label, Phase 2b Study to Compare the Efficacy of DSP107 in Combination with Atezolizumab Versus Fruquintinib in Patients with Advanced Microsatellite Stable Colorectal Cancer (NCT07235293)

This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). Participants will be randomly assigned to receive one of the two treatments, and researchers will monitor how well the cancer responds, how safe the treatments are, and how the body processes them. The study hopes to show that the new combination can improve outcomes for patients with this type of colorectal cancer.

Currently recruiting

DUET-UC

A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colitis (NCT05242484)

Currently recruiting

DURGA-4 D8311C00001

A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell [CAR-T] Therapy Directed Against BCMA and CD19, versus Standard Regimens in Participants with Relapsed Refractory Multiple Myeloma (NCT07391657)

A Phase III, Open-label, Randomised, Multicentre Study Comparing AZD0120 (CAR-T) Therapy Directed Against BCMA and CD19, versus Standard Regimens in Participants with Relapsed Refractory Multiple Myeloma.

Coming soon

Dys-POCUS

Point-of-Care Ultrasound [POCUS]: Reducing Hospital Length of Stay in Patients with Dyspnoea (ACTRN12626000270314)

This study assesses the impact of adding point-of-care ultrasound to the initial assessment of elderly patients admitted with dyspnoea on the hospital length of stay.

Coming soon

DZ2022B0002

A Phase 1, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) (NCT05824585)

Currently recruiting

E-nside INNER-B-APAC

INNER-B-APAC – Asian Pacific post-market clinical follow-up study in patients with thoracoabdominal aortic aneurysms treated with E-nside TAAA Multibranch Stent Graft System (NCT05954793)

No longer recruiting

E-TAN

A double-blinded randomised placebo-controlled trial of estradiol: investigating the effect on disordered eating symptoms of women with anorexia nervosa (ACTRN12623000897662)

Currently recruiting

Easi-Kidney

EASi-Kidney Aldosterone Synthase inhibition and Empagliflozin in CKD (NCT06531824)

Phase 3 study, Aldosterone synthase inhibition with BI 690517 when added to empagliflozin to enhance protection of the heart and slow progression in CKD.

Currently recruiting

ECMO-REHAB

A Randomised Controlled Trial of Early Rehabilitation in Patients on Extracorporeal Membrane Oxygenation (ECMO-Rehab) (NCT05003609)

No longer recruiting

EFC15951

A randomized, Phase 3, open label study evaluating subcutaneous versus intravenous administration of isatuximab in combination with pomalidomide and dexamethasone in adult patients with relapsed and/or refractory multiple myeloma (RRMM) (NCT05405166)

Currently recruiting

EFC17600

A Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, parallel group 48-week extension study to evaluate the treatment response and safety of two amlitelimab dose regimens administered as monotherapy by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis (NCT06407934)

No longer recruiting

eFemoral

A Clinical Evaluation of the Efemoral Vascular Scaffold System [EVSS] for the Treatment of Patients with Symptomatic Peripheral Vascular Disease from Stenosis or Occlusion of the Femoropopliteal Artery (NCT04584632)

This trial is looking at a new treatment called the Efemoral Vascular Scaffold System (EVSS), a tiny dissolvable scaffold coated with medication that helps keep blood flowing in narrowed or blocked leg arteries. VSS is designed to support the artery while it heals and then gradually dissolve, leaving the vessel free to move naturally. This may improve circulation, reduce symptoms like leg pain when walking, and support long-term artery health.

Currently recruiting

EFFECT

Investigating the immunomodulatory and clinical effects of fermentable fibre intervention to reduce symptoms of Long COVID (ACTRN12624000356561)

Currently recruiting

ELEVATE-HFpEF

Randomized trial of ELEVATEd cardiac pacing rate for personalized treatment of Heart Failure with preserved Ejection Fraction [ELEVATE-HFpEF] (NCT06678841)

Currently recruiting

Eli Lilly GZMH

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment with Brenipatide in Delaying Time to Relapse Compared with Placebo in Adult Participants with Major Depressive Disorder (NCT07412756)

A phase 3 Clinical Trial investigating the effectiveness of a GLP-1 drug in preventing or delaying relapse in MDD

Currently recruiting

ELOWEN-1

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care (NCT07332481)

This trial aims to evaluate the safety and efficacy of enpatoran over 24 weeks in people with active cutaneous manifestations of lupus erythematosus with or without systemic disease. Study details include: Study Duration up to 35 weeks, Treatment Duration 24 weeks, Visit Frequency every 4 weeks, with the exception of the Week 2 televisit. Study Intervention Name: Enpatoran, Placebo. Intervention Form: Film-coated tablet.

Coming soon

EMERALD-2

Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who are at high risk of reccurence after curative hepatic resection or ablation (NCT03847428)

Currently recruiting

EMITT-1 GREY WOLF

A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination with Anticancer Treatments in Patients with Solid Malignancies (ACTRN12623000108617)

Currently recruiting